Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Average Recommendation of “Moderate Buy” from Analysts

Both Personalis, Inc. (PSNL) and Bicycle Therapeutics PLC (BCYC) have received an average “Moderate Buy” rating from their respective analysts. PSNL’s eight analysts include six buys, one sell, one hold, with a 12‑month target of $11.00 and a recent target lift by Guggenheim. BCYC’s eleven analysts feature five buys, one strong buy, four holds, one sell, and a 1‑year target of $19.6250.